Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018)
Anaptysbio (ANAB) reported Non-Current Deffered Revenue of $171000.0 for Q4 2018, up 22.14% on a YoY basis from $140000.0 in Q4 2017, and up 5.56% quarter-over-quarter from $162000.0 in Q3 2018.
Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018) Analysis & Trends
Anaptysbio has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $171000.0 in Q4 2018.
- For the quarter ending Q4 2018, Non-Current Deffered Revenue rose 22.14% year-over-year to $171000.0; the trailing twelve-month figure through Dec 2018 stood at $171000.0 (up 22.14% YoY), and the FY2018 full-year result was $171000.0, up 22.14% from the prior year.
- Non-Current Deffered Revenue for Q4 2018 stood at $171000.0, up from $162000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $171000.0 in Q4 2018, with the low at $128000.0 in Q2 2018.
- Historically, Non-Current Deffered Revenue has averaged $151555.6 across 3 years, with a median of $154000.0 in 2016.
- The largest YoY upside for Non-Current Deffered Revenue was 22.14% in 2018 against a maximum downside of 23.81% in 2018.
- Anaptysbio's Non-Current Deffered Revenue stood at $154000.0 in 2016, then dropped by 9.09% to $140000.0 in 2017, then gained by 22.14% to $171000.0 in 2018.
- The last three Non-Current Deffered Revenue figures came in at $171000.0 (Q4 2018), $162000.0 (Q3 2018), and $128000.0 (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 171,000.00 |
| Sep 30, 2018 | 162,000.00 |
| Jun 30, 2018 | 128,000.00 |
| Mar 31, 2018 | 133,000.00 |
| Dec 31, 2017 | 140,000.00 |
| Sep 30, 2017 | 147,000.00 |
| Jun 30, 2017 | 168,000.00 |
| Mar 31, 2017 | 161,000.00 |
| Dec 31, 2016 | 154,000.00 |